# Pizarra — PT-pseudo_cce5d47c05dd (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_cce5d47c05dd
Task: 1

Encounter: Urology - outpatient on 17 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.28 ng/mL²
  - PSA velocity: 3.98 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 42.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8442586 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Obesity (BMI >30), Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: Penicillin (rash)
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.28. Prostate volume 42 mL. csPCa 0.84.

Vitals: weight 86 kg, height 173 cm, BMI 28.7, BP 109/68 mmHg, HR 59 bpm. Smoking: Non-smoker.

Chief complaint: Clinician seeks re-evaluation due to a sustained PSA elevation and a previous biopsy documenting ISUP Grade Group 2 adenocarcinoma.

History: This 61-year-old individual was first evaluated in 2022 after an unexpected PSA elevation surfaced. A subsequent targeted biopsy confirmed disease, with the prior biopsy bucket "Positive", and he now attends for routine surveillance. He reports persistent lower urinary tract symptoms, recording an IPSS score of 20 mainly due to nocturia and a diminished stream, which he currently manages with paracetamol PRN. A retired postal worker, he maintains an active lifestyle that includes weekend hiking and is Married, Lives with partner. His Osteoarthritis remains controlled, and he recently visited podiatry for routine nail care without incident. He is a Non-smoker and maintains Obesity (BMI >30). He explicitly denies unexplained weight loss, bone pain, or haematuria, and abstains completely from alcohol.

Physical examination: Normal DRE; the prostate presents with a symmetrically enlarged, firm, and smooth contour without asymmetry or palpable nodules. General inspection shows stable vital parameters and absence of abdominal masses or lymphadenopathy. Ambulation is independent, although mild bilateral knee crepitus correlates with his established condition.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 20/35 (severe LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.49 +/- 0.16   (95% CI 0.18-0.81)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.16  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of this patient, such as the high PI-RADS score of 5, the high PSA velocity (3.98 ng/mL/yr), and the prior positive biopsy result.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a $p=0.49 \pm 0.16$, placing it in the 'discuss' tier. This suggests the model cannot distinguish between biopsy and no biopsy given the input. This is likely wrong because the patient has a PI-RADS 5 lesion and a rising PSA velocity, which are strong indicators that the prior's low probability is insufficient. The prior fails to account for the clinical significance of the imaging findings and the trajectory of the disease.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What is the prior grade, surveillance pathway, and management agreement?
4. laboratory panel - (Dropped by Moderator, but if retrieved, it might clarify baseline labs).

GUIDELINE ANCHOR
Guidelines suggest that a PSA change alone should not change management based on its weak link with grade progression, but a PSA change, combined with abnormal MRI, should trigger further investigation such as biopsy or repeat MRI.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_cce5d47c05dd", "radiology_report": "Maastricht UMC+ | Radiology | 10 January 2025 | Multiparametric MRI of the Prostate\nClinical Context: Rising prostate-specific antigen (12.0 ng/mL) noted alongside a previous biopsy documenting Gleason 3+4 (ISUP 2). PSA velocity stands at 3.98 ng/mL/yr.\nRESULTS: The gland measures 42.0 mL overall. T2-weighted imaging isolates a focal, hypointense focus roughly 12 x 10 mm situated in the right mid-gland peripheral zone. High b-value DWI shows intense restricted diffusion, mirrored by low ADC signal. DCE sequences highlight rapid, early enhancement followed by prompt washout. Bilateral neurovascular bundles remain preserved. There is no evidence of seminal vesicle invasion, extraprostatic extension, or suspicious pelvic lymphadenopathy.\nCONCLUSION: PI-RADS 5 lesion located in the right mid peripheral zone. PSAD 0.28 ng/mL/mL. csPCa predicted probability 0.8442586."}
get_psa_trend
{"case_id": "PT-pseudo_cce5d47c05dd", "psa_trend": [{"date": "Jun 2022", "val": 1.8}, {"date": "Sep 2023", "val": 4.6}, {"date": "Jan 2025", "val": 12.0}]}
get_previous_notes
{"case_id": "PT-pseudo_cce5d47c05dd", "previous_notes": [{"date": "19 Sep 2024", "author": "Dr. R. Visser (GP)", "text": "Patient attended for routine follow-up after the initial biopsy yielded Gleason 3+4 pathology. Recent laboratory work shows a PSA increase from 7.0 ng/mL in September 2023 to 10.5 ng/mL, which led to scheduling a repeat mpMRI and specialist review. Lower urinary tract symptoms remain bothersome, though no new systemic issues were reported. The complete clinical dossier along with imaging requisitions was transmitted to the urology outpatient department for continued evaluation."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda explicitly dropped this document, and no immediate question arose from the retrieved documents that would necessitate its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion located in the right mid peripheral zone.
- PSA trend: Rising trend from 4.6 ng/mL (Sep 2023) to 12.0 ng/mL (Jan 2025), with a velocity of 3.98 ng/mL/yr.
- Previous notes: Prior biopsy showed Gleason 3+4 (ISUP 2), and the patient is on a surveillance pathway following a PSA rise.

AGAINST sampling this patient now:
- MRI report: No evidence of seminal vesicle invasion, extraprostatic extension, or suspicious pelvic lymphadenopathy.

WHERE THIS LEANS
The combination of a high-risk PI-RADS 5 lesion and a significant rising PSA velocity strongly supports further investigation, contradicting the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI, PSA trend, previous notes) strongly support a biopsy based on the PI-RADS 5 finding and significant PSA velocity, contradicting the initial statistical prior. The record is sufficient to proceed to the final decision.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of this patient, such as the high PI-RADS score of 5, the high PSA velocity (3.98 ng/mL/yr), and the prior positive biopsy result.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a $p=0.49 \pm 0.16$, placing it in the 'discuss' tier. This suggests the model cannot distinguish between biopsy and no biopsy given the input. This is likely wrong because the patient has a PI-RADS 5 lesion and a rising PSA velocity, which are strong indicators that the prior's low probability is insufficient. The prior fails to account for the clinical significance of the imaging findings and the trajectory of the disease.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What is the prior grade, surveillance pathway, and management agreement?
4. laboratory panel - (Dropped by Moderator, but if retrieved, it might clarify baseline labs).

GUIDELINE ANCHOR
Guidelines suggest that a PSA change alone should not change management based on its weak link with grade progression, but a PSA change, combined with abnormal MRI, should trigger further investigation such as biopsy or repeat MRI.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Maastricht UMC+ | Radiology | 10 January 2025 | Multiparametric MRI of the Prostate. The report identifies a PI-RADS 5 lesion located in the right mid peripheral zone, measuring 12 x 10 mm. It notes no evidence of seminal vesicle invasion, extraprostatic extension, or suspicious pelvic lymphadenopathy.
get_psa_trend
The serial PSA trend shows values of 1.8 ng/mL (Jun 2022), 4.6 ng/mL (Sep 2023), and 12.0 ng/mL (Jan 2025), indicating a significant rising trend leading to the current PSA of 12.0 ng/mL.
get_previous_notes
The previous notes document that the initial biopsy yielded Gleason 3+4 (ISUP 2) pathology. The patient is on a surveillance pathway following a PSA rise, and a repeat mpMRI was scheduled.

NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda explicitly dropped this document, and no immediate question arose from the retrieved documents that would necessitate its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion located in the right mid peripheral zone.
- PSA trend: Rising trend from 4.6 ng/mL (Sep 2023) to 12.0 ng/mL (Jan 2025), with a velocity of 3.98 ng/mL/yr.
- Previous notes: Prior biopsy showed Gleason 3+4 (ISUP 2), and the patient is on a surveillance pathway following a PSA rise.

AGAINST sampling this patient now:
- MRI report: No evidence of seminal vesicle invasion, extraprostatic extension, or suspicious pelvic lymphadenopathy.

WHERE THIS LEANS
The combination of a high-risk PI-RADS 5 lesion and a significant rising PSA velocity strongly supports further investigation, contradicting the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly supports a biopsy based on the PI-RADS 5 finding and significant PSA velocity, contradicting the initial statistical prior. The disagreement is about the interpretation of this evidence, which is now settled by the retrieved documents.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The evidence strongly leans toward biopsy due to the PI-RADS 5 finding and the significant PSA velocity of 3.98 ng/mL/yr, which contradicted the statistical prior suggesting no biopsy. The statistical prior suggested no biopsy, while the retrieved evidence pointed to sampling. The disagreement was resolved by the retrieved documents showing a high-risk lesion and rising PSA trajectory, which overturned the prior's suggestion.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
